1.6 Percentage of patients with atrial fibrillation that are discharged on oral anticoagulants

Purpose
This indicator addresses effectiveness of processes that encourage judicious use of preventive pharmacotherapy in patients at risk of stroke.

Background and evidence
Under-utilisation of anticoagulation continues to be an issue in people with atrial fibrillation (AF).1-3 Anticoagulants reduce the risk of stroke by about two thirds compared to aspirin which reduces risk of stroke by about one fifth.4,5 The benefits of warfarin are not offset by increased bleeding in the majority of patients.5 Older people, provided they are carefully monitored, can use anticoagulants with reasonable safety;7-10 however, patients over 80 years of age are at greater risk of adverse events.11 Direct oral anticoagulants (dabigatran, rivaroxaban and apixaban) have demonstrated non-inferiority to warfarin in stroke prevention and show lower rates of intracranial haemorrhage.8-10 They are alternative therapeutic options to warfarin in selected patients.

Key definitions
Patients with atrial fibrillation refers to patients less than 80 years of age admitted with permanent (chronic), persistent or paroxysmal (intermittent) AF4,5 as a primary or secondary diagnosis.

Oral anticoagulants refer to orally administered vitamin K antagonists such as warfarin, direct thrombin inhibitors such as dabigatran and direct Factor Xa inhibitors such as apixaban and rivaroxaban. Newer medicines may be included within these oral anticoagulant classes as they become licensed for clinical use in stroke prevention in nonvalvular atrial fibrillation in Australia.

Discharged on oral anticoagulants means there is documentation in the discharge summary or letter at the time of transfer to the community, residential care or another hospital that an oral anticoagulant is to be taken on an ongoing basis. A supply of oral anticoagulant may or may not be provided by the hospital.

Data collection for local use
Please refer to the section Using the National Quality Use of Medicines Indicators for Australian Hospitals for guidance on sample selection, sample size, measurement frequency and other considerations.

Inclusion criteria: Discharged patients aged between 18 and 80 years of age with a primary or secondary diagnosis of AF.

Exclusion criteria: Patients less than 65 years of age diagnosed with lone AF.

Recommended data sources: Medical records and discharge documentation.

The data collection tool for QUM Indicator 1.6 assists data collection and indicator calculation.
Data collection for inter-hospital comparison

This indicator may be suitable for inter-hospital comparison. In this case, definitions, sampling methods and guidelines for audit and reporting need to be agreed in advance in consultation with the coordinating agency.

Indicator calculation

\[
\text{Numerator} = \frac{\text{Number of patients with AF that are discharged on an oral anticoagulant}}{\text{Denominator}} \times 100\%
\]

Numerator = Number of patients with AF that are discharged on an oral anticoagulant

Denominator = Number of patients discharged with AF in sample

Limitations and interpretation

This indicator examines patients less than 80 years because the risk of bleeding increases after this age, and stroke prevention in this age group is complex and challenging. Antithrombotic therapy is not recommended in patients aged less than 65 years with lone AF; hence their exclusion from the sample. Anti-platelet agents have not been included as acceptable alternatives to oral anticoagulants because there is clear evidence of the superiority of anticoagulation.

Consideration of potential contraindications requires a detailed review of risks associated with anticoagulation and specific risks related to each oral anticoagulant. If an oral anticoagulant is not prescribed for the patient on discharge, the reason(s) for omission, such as a contra-indication or a plan to initiate therapy in the future, should be documented in the patient’s discharge summary or letter.

Further information

A number of issues need to be considered when evaluating the appropriateness of oral anticoagulants for individual patients. Table 1 outlines a scoring system that may be used to calculate the risk of stroke in patients with AF. Table 2 outlines a scoring system that may be used to calculate bleeding risk. Unfortunately, as the risk of thromboembolism rises, so the risk of bleeding also tends to rise. Absolute and relative contraindications related to a patient’s medical condition, functional and cognitive status, and capability to manage their medicines need to be taken into account when evaluating individual patient risk.

The Medication Safety Self Assessment for Antithrombotic Therapy in Australian Hospitals (MSSA-AT) can help identify potential strategies for improvement with this and other indicators. The MSSA-AT encourages development of robust systems for safe prescribing, dispensing, administration and monitoring of antithrombotic therapy. The MSSA-AT is available at [www.cec.health.nsw.gov.au](http://www.cec.health.nsw.gov.au)

This indicator can be used to assist hospitals in meeting the National Safety and Quality Health Service Standard 1 [items 1.2.1, 1.2.2, 1.5.2, 1.6.1, 1.6.2] and Standard 4 [items 4.2.1, 4.2.2, 4.5.1, 4.5.2].
Table 1: Risk factors for stroke in patients with atrial fibrillation: the CHA<sub>2</sub>DS<sub>2</sub>-VASc scoring system<sup>19</sup>

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>Congestive heart failure/left ventricular dysfunction</td>
</tr>
<tr>
<td>H</td>
<td>Hypertension</td>
</tr>
<tr>
<td>A&lt;sub&gt;2&lt;/sub&gt;</td>
<td>Age ≥75 years</td>
</tr>
<tr>
<td>D</td>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td>S&lt;sub&gt;2&lt;/sub&gt;</td>
<td>Stroke/Transient Ischaemic Attack/Thromboembolism</td>
</tr>
<tr>
<td>V</td>
<td>Vascular disease – coronary artery disease (prior myocardial infarction, peripheral artery disease, or aortic plaque)</td>
</tr>
<tr>
<td>A</td>
<td>Age 65–74 years</td>
</tr>
<tr>
<td>Sc</td>
<td>Sex category (i.e. female gender)</td>
</tr>
<tr>
<td><strong>Maximum Score</strong></td>
<td><strong>9</strong></td>
</tr>
</tbody>
</table>

* Maximum score is 9 as age may contribute 0, 1, or 2 points.

The European Society of Cardiology (ESC) 2012 focused update of the Guidelines for the management of atrial fibrillation recommends oral anticoagulation if the CHA<sub>2</sub>DS<sub>2</sub>-VASc is equal to or greater than one, unless a score of one is due to female gender.<sup>12</sup>

When considering the use of thromboprophylaxis the risk of stroke needs to be balanced against the risk of major bleeding, particularly intracranial haemorrhage.<sup>20</sup> The ESC guidelines recommend the use of the HAS-BLED score to determine bleeding risk and identify modifiable risk factors and monitoring requirements.<sup>12</sup>

Table 2: Risk factors for bleeding: the HAS-BLED scoring system<sup>21,22</sup>

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>H</td>
<td>Hypertension History? (uncontrolled, &gt;160 mmHg systolic)</td>
</tr>
<tr>
<td>A</td>
<td>Renal Disease? (Dialysis, transplant, Cr &gt;200 micromol/L)</td>
</tr>
<tr>
<td></td>
<td>Liver Disease? (Cirrhosis, Bilirubin &gt;2x Normal, AST/ALT/AP &gt;3x Normal)</td>
</tr>
<tr>
<td>S</td>
<td>Stroke History?</td>
</tr>
<tr>
<td>B</td>
<td>Prior Major Bleeding or Predisposition to Bleeding?</td>
</tr>
<tr>
<td>L</td>
<td>Labile INR? (Unstable/high INRs, &lt;60% time in therapeutic range)</td>
</tr>
<tr>
<td>E</td>
<td>Age ≥65?</td>
</tr>
<tr>
<td>D</td>
<td>Medication Usage Predisposing to Bleeding? (Antiplatelet agents, NSAIDs, corticosteroids)</td>
</tr>
<tr>
<td></td>
<td>Alcohol Usage History?</td>
</tr>
<tr>
<td><strong>Maximum Score</strong></td>
<td><strong>9</strong></td>
</tr>
</tbody>
</table>

Cr=Serum creatinine; AST=Aspartate aminotransferase; ALT= Alanine aminotransferase; AP=Alkaline phosphatase

HAS-BLED stands for hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly (age over 65), and drugs/alcohol.
References:
5. eTG complete [Internet]. Melbourne: Therapeutic Guidelines Limited; 2013 November.